Warnex Inc.

Warnex Inc.

January 17, 2007 11:38 ET

Warnex to perform pharmacogenetic services for Schering-Plough Canada

LAVAL, QC, Jan. 17 - Warnex Inc. (TSX: WNX) today announced that
its Medical Laboratories division will develop new pharmacogenetic assays and
serve as a central laboratory for several clinical studies of Schering-Plough
Canada, a leader in the discovery and development of pharmaceutical products.

"Pharmacogenetic assays allow the correlation of different responses to
drugs with genetic diversity and/or mutations, improving the overall process
of drug development," said Mark Busgang, President and CEO of Warnex. "In
2006, Warnex acquired PRO-DNA Diagnostics, a laboratory offering genetic
testing services, in order to enter the pharmacogenetics market. These new
projects with Schering-Plough Canada validate our strategy to develop our
presence in this growing market."

Pharmacogenetics helps to predict whether a patient will have a good
response to a drug, a bad response to a drug or no response at all. According
to the U.S. Food and Drug Administration Center for Drug Evaluation and
Research, over 2 million Adverse Drug Reactions ("ADRs") occur yearly leading
to more than 100,000 deaths yearly. ADRs are one of the leading causes of
hospitalization and death ahead of pulmonary disease, diabetes, AIDS and
pneumonia in the United States. By employing pharmacogenetic studies in drug
development, companies can increase the likelihood of a positive study result
by matching patients who are more likely to respond or alternatively not more
likely not to have an adverse event.

Warnex Medical Laboratories will provide pharmacogenetic and molecular
biology services during Schering-Plough Canada's clinical trials for drugs
related to the treatment of different types of cancer and infectious diseases.

Warnex Medical Laboratories focuses on genetic and biochemical testing
for the healthcare industry. The division performs testing in a wide range of
clinical specialties, including endocrinology, haematology, infectious
diseases, obstetrics/gynaecology, and oncology, and has extensive expertise in
genetic testing for human identification, molecular medicine, and
pharmacogenetics.

About Schering-Plough Canada

Schering-Plough Canada (www.schering-plough.ca) is a country operation of
Schering-Plough Corporation that employs over 850 people across Canada.

Schering-Plough is a global science-based health care company with
leading prescription, consumer and animal health products. Through internal
research and collaborations with partners, Schering-Plough discovers,
develops, manufactures and markets advanced drug therapies to meet important
medical needs. Schering-Plough's vision is to earn the trust of the
physicians, patients and customers served by its more than 32,000 people
around the world. The headquarters are based in Kenilworth, NJ, and its
website is www.schering-plough.com.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
DNA-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, integration of acquisitions, manufacturing and
laboratory facilities, suppliers, key employees, key customers and business
partners, financial resources and credit risk, government regulations, foreign
currency risk and volatility of share price, and other important factors that
could cause actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis for the third
quarter ended September 30, 2006, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated
results expressed in these forward-looking statements.

Contact Information